Pharming Group to participate in June investor conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharming Group N.V. (Nasdaq: PHAR) announced its participation in three key investor conferences in June 2024. CEO Sijmen de Vries will present at the Jefferies Healthcare Conference in New York on June 5. CMO Anurag Relan will join a panel at the Oppenheimer Novel Targets in Immunology Summit on June 24. Additionally, Pharming will attend the Oppenheimer 2024 Montauk Life Sciences Summit from June 26-28. These events aim to provide investors with insights into the company's progress and future plans. Live webcasts and replays will be available on Pharming's website.
Positive
- Pharming will gain exposure through high-profile investor conferences.
- CEO and CMO participation indicates active leadership engagement.
- Live webcasts and replays increase accessibility for global investors.
Negative
- No concrete financial or clinical data updates provided.
- Potentially high travel and participation costs with unclear ROI.
- Focus on presentations without mention of new strategic initiatives or product launches.
Details
News Market Reaction – PHAR
On Jun 3, the day this news came out, PHAR closed 0.93% above the previous close.
Data tracked by StockTitan Argus for the Jun 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June:
- Jefferies Healthcare Conference, New York, USA, June 5-6, 2024
Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
- Oppenheimer Novel Targets in Immunology Summit, New York, USA, June 24, 2024
Anurag Relan, Chief Medical Officer, will participate in the panel “Taking the Inflammation out of I&I - Novel Approaches for Inflammatory Disorders” on Monday, June 24 at 13:30EDT/19:30CEST.
- Oppenheimer 2024 Montauk Life Sciences Summit, Montauk, NY, USA, June 26-28, 2024
For more information about these conferences, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies or Oppenheimer representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.